Driving Improved Outcomes in Resectable Melanoma: Pathways for Optimized Adjuvant Immunotherapy Strategies

Share

Program Content

Activities

  • Melanoma Adjuvant Immunotherapy
    Driving Improved Outcomes in Resectable Melanoma: Pathways for Optimized Adjuvant Immunotherapy Strategies
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 28, 2023

    View Activity

Faculty

cover img faculity

Michael A. Davies, MD, PhD

Professor and Chair, Department of Melanoma Medical Oncology
Professor, Translational Molecular Pathology and Genomic Medicine
Anne and John Mendelsohn Chair in Cancer Research
University of Texas, MD Anderson Cancer Center
Houston, Texas

cover img faculity

April Salama, MD

Associate Professor of Medicine
Division of Medical Oncology
Director, Melanoma Program
Duke Cancer Institute
Durham, North Carolina

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC, in partnership with AIM at Melanoma Foundation.

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Partners

AIM at Melanoma Foundation

ProCE Banner